Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 14;107(6):1397–1409. doi: 10.3324/haematol.2021.279229

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — Renal response in the isatuximab (Isa) carfilzomib (K) dexamethasone (d) (Isa-Kd) compared with Kd arms. (A) Complete and durable (≥60 days) renal responses in patients with eGFR <50 mL/min/1.73 m² at baseline and minor renal responses in patients with eGFR ≥15 and <30 mL/min/1.73 m² at baseline, (ITT population). (B) Time to first renal response and (C) time to first complete renal response in patients with eGFR <50 mL/min/1.73 m² at baseline. CrR: complete renal response; d: dexamethasone; eGFR: estimated glomerular filtration rate; Isa: isatuximab; ITT: intent to treat; K: carfilzomib; rR: renal response.